Retham Technologies launched its next-generation Retham Cryoplatelets™ and appointed Prolytix as its distributor. The update is operational rather than financial, implying modest near-term upside with limited likely market movement.
Retham Technologies launched its next-generation Retham Cryoplatelets™ and appointed Prolytix as its distributor. The update is operational rather than financial, implying modest near-term upside with limited likely market movement.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
